Medifast Cuts Costs as Coach Numbers Fall
The weight-loss company reported $72 million in third-quarter 2026 revenue while executing a cost realignment program.
Updated on Nov. 3, 2026 in Corporate Finance
Medifast reported $72 million in third-quarter 2026 revenue on an October 26, 2026 earnings call. The company executed Project Catalyst, a cost realignment program, as active earning coach numbers declined.
Why it matters
Declining coach numbers must be offset to maintain profitability, and the cuts aim to make lower operating expense levels permanent. The changes signal how a direct-selling health company is adjusting its model as its field network shrinks.
The figures come from Medifast's third-quarter 2026 earnings filing, showing revenue of $72 million and active earning coaches down to 10.2 thousand from 19.5 thousand a year earlier. Revenue per active coach rose 54.1% to $7.06 thousand, while the company's exact savings from the cost program were not disclosed.
The players
Medifast
Medifast is a publicly traded weight-management company that sells meal replacement products through a network of independent coaches.
The details
Medifast simplified its commission plan to focus on high-performing leaders and closed facilities, reduced its workforce, and eliminated nonstrategic software applications under Project Catalyst. The company also launched Trilogy, its metabolic health brand, and MetaVantage, a proprietary ingredient platform, while leveraging artificial intelligence to streamline operations.
Timeline
- Third quarter 2026: Project Catalyst executed and quarterly revenue reported.
- October 26, 2026: Medifast held its third-quarter earnings call.
- Before year-end 2026: The company expects structural changes to yield positive results.
Market Dynamics
Medifast's shrinking coach network reflects the pressure on direct-selling weight-management companies that depend on independent sellers to drive revenue. The cost realignment and simplified commission structure show a company adjusting its model to keep margins intact as its field force contracts.
Investors tracking Medifast should watch whether the company's debt-free balance sheet, which holds $172.5 million in cash, supports its planned return to growth. Shareholders will want to see if the cost cuts and simplified commission plan translate into the positive results management has projected before year-end.
The takeaway
Medifast's results show that cutting costs can protect profitability when a sales network shrinks, but sustained growth depends on rebuilding coach productivity. Readers following the company should track whether its projected year-end improvements appear in future reports.
Further reading
For more on company earnings and cost strategies, see Corporate Finance.
Source note: This article includes information reported by The Motley Fool.
